News
CRDF
--
0.00%
--
Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors
/PRNewswire/ --(Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant pros...
PR Newswire - PRF · 3d ago
BRIEF-Cardiff Oncology Announces First Patient Dosed In A Phase 2 Trial Of Onvansertib In Combination With Irinotecan And 5-Fu In Pancreatic Cancer
reuters.com · 5d ago
Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer
/PRNewswire/ -- (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant pro...
PR Newswire - PRF · 5d ago
Cardiff Oncology Doses First Patient in Mid-Stage Study of Onvansertib Combination Therapy for Pancreatic Cancer
MT Newswires · 5d ago
Are Options Traders Betting on a Big Move in Cardiff Oncology (CRDF) Stock?
Zacks.com · 05/24 12:35
YALA, OBLN, ONTX and CRDF among midday movers
Gainers: Annovis Bio (ANVS) +250%.Jiuzi Holdings (JZXN) +27%.Longeveron (LGVN) +25%.Wah Fu Education (WAFU) +22%.Mesa Royalty Trust (MTR) +20%.Gracell Biotechnologies (GRCL) +20%.Obalon Therapeutics (OBLN) +16%.Yalla Group (YALA) +16%.VOC Energy Trust (VOC...
Seekingalpha · 05/21 16:42
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 05/21 16:37
Cardiff Oncology to Present at the Jefferies Virtual Healthcare Conference
, /PRNewswire/ --(Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant p...
PR Newswire - PRF · 05/20 12:30
Corriente Advisors, LLC Buys Teledyne Technologies Inc, Facebook Inc, Cue Biopharma Inc, Sells ...
GuruFocus News · 05/19 15:38
Elkhorn Partners Limited Partnership Buys International Flavors & Fragrances Inc, Amazon. ...
GuruFocus News · 05/11 20:38
Cardiff Oncology (CRDF) Gets a Buy Rating from H.C. Wainwright
SmarterAnalyst · 05/10 12:27
HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Lowers Price Target to $25
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and lowers the price target from $27 to $25.
Benzinga · 05/10 11:13
--HC Wainwright Adjusts Cardiff Oncology PT to $25 From $27, Maintains Buy Rating
MT Newswires · 05/10 09:28
Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates
Zacks.com · 05/06 23:05
Cardiff Oncology Q1 EPS $(0.14) Up From $(0.41) YoY
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.14) per share. This is a 65.85 percent increase over losses of $(0.41) per share from the same period last year.
Benzinga · 05/06 21:24
Cardiff Oncology EPS beats by $0.01, misses on revenue
Cardiff Oncology (CRDF): Q1 GAAP EPS of -$0.14 beats by $0.01.Revenue of $0.07M (flat Y/Y) misses by $0.08M.Press Release
Seekingalpha · 05/06 21:24
Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resist...
PR Newswire · 05/06 20:10
10-Q: CARDIFF ONCOLOGY, INC.
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Forward-Looking Statements This...
Edgar Online - (EDG = 10Q, 10K) · 05/06 20:02
Webull provides a variety of real-time CRDF stock news. You can receive the latest news about Cardiff Oncology Inc through multiple platforms. This information may help you make smarter investment decisions.
About CRDF
Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). Its programs include the development of onvansertib in a Phase-I b/2 study of onvansertib in combination with FOLFIRI/Avastin in mCRC; a Phase II study of onvansertib in combination with Zytiga (abiraterone)/prednisone in Zytiga-resistant mCRPC, and a Phase-II study of onvansertib in combination with decitabine in AML.